Unicycive Therapeutics (UNCY) to Release Quarterly Earnings on Monday

Unicycive Therapeutics (NASDAQ:UNCY) is projected to issue its results before the market opens on Monday, March 30th. Analysts expect the company to announce earnings of ($0.46) per share for the quarter.

Unicycive Therapeutics Stock Down 1.2%

Shares of Unicycive Therapeutics stock opened at $6.73 on Monday. The firm has a market cap of $144.63 million, a PE ratio of -1.70 and a beta of 1.82. Unicycive Therapeutics has a twelve month low of $3.71 and a twelve month high of $11.00. The business has a 50-day moving average price of $6.63 and a 200 day moving average price of $5.66.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Lazard Asset Management LLC acquired a new stake in Unicycive Therapeutics in the 2nd quarter worth about $55,000. JPMorgan Chase & Co. raised its holdings in shares of Unicycive Therapeutics by 11,698.4% during the second quarter. JPMorgan Chase & Co. now owns 21,709 shares of the company’s stock valued at $104,000 after acquiring an additional 21,525 shares during the last quarter. Citadel Advisors LLC acquired a new position in shares of Unicycive Therapeutics during the third quarter valued at approximately $182,000. Quadrature Capital Ltd purchased a new position in shares of Unicycive Therapeutics in the fourth quarter valued at approximately $226,000. Finally, State Street Corp lifted its position in shares of Unicycive Therapeutics by 19.0% in the fourth quarter. State Street Corp now owns 65,227 shares of the company’s stock valued at $376,000 after acquiring an additional 10,400 shares in the last quarter. 40.42% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have commented on UNCY. Westpark Capital began coverage on Unicycive Therapeutics in a report on Thursday, February 19th. They issued a “buy” rating on the stock. Guggenheim reaffirmed a “buy” rating on shares of Unicycive Therapeutics in a research note on Tuesday, December 30th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Unicycive Therapeutics in a research report on Monday, December 29th. Four investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $34.33.

Unicycive Therapeutics Company Profile

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.